top stories

Part club, part guide, part land­lord: Arie Bellde­grun is blue­print­ing a string of be­spoke biotech com­plex­es in glob­al boom­towns — start­ing with Boston

6 hours ago
People
Venture

H1 analy­sis: The high-stakes ta­ble in the biotech deals casi­no is pay­ing out some record-set­ting win­nings

3 hours ago
Deals

Roche's Genen­tech goes on deal spree, un­veil­ing third deal on the same day

4 hours ago
Deals

Genen­tech inks its lat­est dis­cov­ery deal — this time turn­ing to RNA up­start Sky­hawk

6 hours ago
Deals
Discovery

Latest

Most read

UP­DAT­ED: Gilead un­leash­es a $5B late-stage cash al­liance with Gala­pa­gos — lay­ing out O'­Day's R&D strat­e­gy

Yesterday
Deals
Pharma

AI-fo­cused No­table Labs score $40M in fund­ing; Seat­tle Ge­net­ics/Astel­las sub­mit mar­ket­ing ap­pli­ca­tion for en­for­tum­ab ...

4 hours ago
Protocols

UP­DAT­ED: As ri­vals march on, No­var­tis se­cures pri­or­i­ty FDA re­view for sick­le cell dis­ease ther­a­py

5 hours ago
R&D
Regulatory

Keen to stay out front in cell ther­a­py, Gilead­'s Kite builds its own vi­ral vec­tor man­u­fac­tur­ing op­er­a­tions

5 hours ago
Cell/Gene Tx

San Diego oph­thalmic biotech up­start rais­es $28M on al­ter­na­tive to corneal trans­plant

6 hours ago
Startups
Venture

Deal hun­gry So­sei Hep­tares brings Roche's Genen­tech on board as a part­ner

7 hours ago
Deals
see latest stream
People

Takeda's trans­la­tion­al cell ther­a­py group revs up for a race to the clin­ic with off-the-shelf CAR-T

12 hours ago

GSK to tap Jonathan Symonds as chair­man, lever­ag­ing Big Phar­ma ex­pe­ri­ence for con­sumer biz deal

Yesterday

Fresh out of Eli Lil­ly, Christi Shaw sur­faces as Daniel O'­Day's new CEO at CAR-T pi­o­neer Kite

4 days ago
Startups

Pe­ter Kolchin­sky and Raj Shah raise a $300M fund de­vot­ed to biotech star­tups

Yesterday

Can a Medicare Ad­van­tage in­sur­er be great at drug de­vel­op­ment for their tar­get au­di­ence?

5 days ago

Medicxi, Tai­ho in­fuse €30M in­to Evotec spin­out — eye­ing can­cer meds tar­get­ing DNA dam­age re­sponse path­ways

Last week
Deals

Boehringer buys Swiss biotech in its lat­est M&A deal, go­ing the next-gen can­cer vac­cine route

Yesterday

Ab­b­Vie beefs up the on­col­o­gy pipeline, bag­ging an up­start STING play­er with its own unique ap­proach

Yesterday

KRAS G12C is the hot new play in can­cer R&D, and No­var­tis jumps in with a com­bo deal

6 days ago
IPOs

Gen­mab steps up for a $500M IPO haul, with its sights on a record-set­ting mar­ket cap

6 days ago

In a first, HKEX re­ceives IPO pitch from lo­cal biotech look­ing to make it big in crowd­ed an­ti­bod­ies field

Last week

Puretech-backed Karuna makes Nas­daq de­but with $89M IPO

3 weeks ago

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

The top 15 mega-deals in bio­phar­ma: Ab­b­Vie and Bris­tol-My­ers ac­qui­si­tions stir fresh de­bate over what's too big to ...

3 weeks ago
Deals

Gene ther­a­py R&D deals turn red hot as Big Phar­ma steps up to play

5 weeks ago
Cell/Gene Tx
Deals

Bio­phar­ma BD teams are speed­ing in­to the fast lane — cash in hand — as deal­mak­ing con­tin­ues to heat up in Q1 ...

2 months ago
Pharma

The top 50 biotechs by mar­ket cap — and what their CEOs’ com­pen­sa­tion deals tell us about bio­phar­ma

2 months ago
People

Don't missSee all

Am­gen, No­var­tis scrap Alzheimer's stud­ies — is BACE fi­nal­ly dead or will Bio­gen and Ei­sai car­ry on?

4 days ago
R&D

Al­ny­lam’s Maraganore switch­es ‘per­haps the best CFO in mid-cap biotech’ with Shire vet Jeff Poul­ton

5 days ago
People

Analy­sis: In most of the Big Phar­ma world, R&D spend­ing tow­ers over rev­enue from new drugs. Guess who beat the odds

5 days ago
Biotech Voices
Pharma

White House changes course to kill re­bate re­form

5 days ago
Pharma

Peer review See all

Jul
12

Ex-DARPA di­rec­tor pur­sues all-in-one can­cer pill as NED CEO; Karyopharm los­es com­mer­cial chief ahead of drug roll­out

Jul
3

Gold­man Sach­s' Ankang Li heads to biotech Terns as new CFO; SV re­cruits new part­ner for De­men­tia Dis­cov­ery Fund

Jun
28

Evan Loh climbs the lad­der to be­come CEO at Paratek Phar­ma­ceu­ti­cals; Co­di­ak's Doug Williams takes chair­man's role at AC Im­mune

Jun
21

Maze in­ter­im chief Charles Hom­cy pass­es ba­ton to Ja­son Colo­ma; William Col­lier tapped as CEO of Ar­bu­tus

Jun
14

Tariq Kas­sum jumps from Ob­sid­i­an to Cel­sius helm; Quell Ther­a­peu­tics taps Iain McGill as new CEO

R&D channel feed

Yesterday

Hal Bar­ron's team at GSK scores a win with pos­i­tive Ze­ju­la PhI­II front­line study — now comes the hard part

Score one for Hal Bar­ron and the new R&D team steer­ing Glax­o­SmithK­line’s pipeline. The phar­ma gi­ant re­port­ed this morn­ing that its re­cent­ly ac­quired PARP, Ze­ju­la ...

READ MORE

FDA bats back As­traZeneca's SGLT di­a­betes drug for Type 1 di­a­betes — block­ing a class on safe­ty fears

Yesterday

Broad star Feng Zhang un­veils a new CRISPR plat­form, edit­ing RNA and elim­i­nat­ing Alzheimer's threat — in cells

4 days ago
latest in R&D

Mi­cro­cap Capri­cor soars on in­ter­im PhII DMD da­ta show­ing func­tion­al ben­e­fit for old­er pa­tients

Yesterday
Cell/Gene Tx

Eton Phar­ma hand­ed CRL for re­for­mu­lat­ed con­junc­tivi­tis eye drop

Yesterday
Regulatory

Scripps-led con­sor­tium scores $129M NIH grant to work on vac­cine for stub­born HIV

5 days ago

Faced with a PhI­II flop in NASH, Gilead is se­quenc­ing 15,000 pa­tients to find new drugs

5 days ago

Open­ing new bat­tle­front with Gilead, GSK touts new Dova­to non-in­fe­ri­or­i­ty da­ta months af­ter first ap­proval

6 days ago
see latest stories

Pharma channel feed

4 days ago

UP­DAT­ED: ICER up­date on Duchenne drugs push­es up price es­ti­mates for Ex­ondys 51, Em­flaza ahead of Ju­ly pan­el re­view

In­creas­ing­ly in­flu­en­tial drug cost-ef­fec­tive­ness watch­dog ICER still does­n't think that the drugs ap­proved to treat Duchenne mus­cu­lar dy­s­tro­phy have so far proved their val­ue to pa­tients. ...

READ MORE

New peanut al­ler­gy ther­a­pies aren’t as ef­fec­tive — or near­ly as in­ex­pen­sive — as ab­sti­nence, says ICER

5 days ago

Sup­ply con­straints push EpiPen ri­val mak­er Am­neal to re­struc­ture, shares fall

6 days ago
latest in Pharma

Fed­er­al judge scut­tles Trump's rule man­dat­ing drug prices in TV ads

Last week
Regulatory

Ex­ec­u­tive or­der un­der con­struc­tion to peg US drug prices to low­est prices abroad, Trump says

Last week

Alex­ion's cash cow Soliris just got fat­ter as FDA green­lights an­oth­er block­buster in­di­ca­tion

3 weeks ago

Sanofi/Re­gen­eron mus­cle ahead of a ri­val No­var­tis/Roche team, win first ap­proval in key rhi­nos­i­nusi­tis field

3 weeks ago

Bris­tol-My­ers star Op­di­vo fails sur­vival test in a matchup with Nex­avar aimed at shak­ing up the big HCC mar­ket

4 weeks ago
R&D
see latest stories